La Jolla Pharmaceutical Co.
(NASDAQ : LJPC)

( )
LJPC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.45%98.560.0%$1438.14m
BIIBBiogen, Inc. -0.36%242.511.7%$630.38m
AMGNAmgen, Inc. -0.79%220.461.3%$568.17m
GILDGilead Sciences, Inc. 0.60%60.251.0%$535.76m
VRTXVertex Pharmaceuticals, Inc. -0.63%216.501.9%$470.81m
REGNRegeneron Pharmaceuticals, Inc. -3.34%506.102.7%$447.76m
BNTXBioNTech SE -4.35%101.870.0%$424.45m
ILMNIllumina, Inc. 1.25%305.633.5%$377.98m
NVAXNovavax, Inc. 1.44%95.3392.9%$339.05m
EXASEXACT Sciences Corp. -2.72%117.2619.6%$289.27m
MGENMiragen Therapeutics, Inc. -4.62%16.500.7%$248.55m
SRRKScholar Rock Holding Corp. 3.14%42.700.0%$242.63m
APVOAptevo Therapeutics, Inc. -3.58%43.9218.3%$210.20m
SGENSeagen Inc. -2.05%164.635.8%$167.34m
ALXNAlexion Pharmaceuticals, Inc. 0.41%123.112.0%$161.56m

Company Profile

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.